David A. Siegel Cullinan Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 19,600 shares of CGEM stock, worth $319,676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,600
Previous 38,600
49.22%
Holding current value
$319,676
Previous $393,000
15.27%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CGEM
# of Institutions
118Shares Held
42.8MCall Options Held
12.6KPut Options Held
4.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$125 Million21.33% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$55.7 Million15.23% of portfolio
-
Bvf Inc San Francisco, CA3.2MShares$52.1 Million1.63% of portfolio
-
Blue Owl Capital Holdings LP New York, NY2.92MShares$47.7 Million13.21% of portfolio
-
Franklin Resources Inc San Mateo, CA2.7MShares$44 Million0.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $744M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...